Revolution Medicines, Inc. (NASDAQ: RVMD) reported Q4 EPS of ($0.63), $0.19 better than the analyst estimate of ($0.82). Revenue for the quarter came in at $15.33 million versus the consensus estimate of $7.8 million.

For earnings history and earnings-related data on Revolution Medicines, Inc. (RVMD) click here.